CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Sodium Chloride 9mg/mLWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug359 Hydrocortisone Wiki 0.58

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D000860 Hypoxia NIH 0.33

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial

We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.

NCT04348305 Covid-19 Hypoxia Drug: Hydrocortisone Drug: Sodium Chloride 9mg/mL
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28

Measure: Days alive without life support at day 28

Time: Day 28 after randomisation

Secondary Outcomes

Description: Death from all causes

Measure: All-cause mortality at day 28

Time: Day 28 after randomisation

Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90

Measure: Days alive without life support at day 90

Time: Day 90 after randomisation

Description: Death from all causes

Measure: All-cause mortality at day 90

Time: Day 90 after randomisation

Description: Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction

Measure: Number of participants with one or more serious adverse reactions

Time: Day 14 after randomisation

Description: Number of days alive and out of hospital not limited to the index admission

Measure: Days alive and out of hospital at day 90

Time: Day 90 after randomisation

Description: Death from all causes

Measure: All-cause mortality at 1 year after randomisation

Time: 1 year after randomisation

Description: Assessed by EQ-5D-5L

Measure: Health-related quality of life at 1 year

Time: 1 year after randomisation

Description: Assessed by EQ-VAS

Measure: Health-related quality of life at 1 year

Time: 1 year after randomisation


Related HPO nodes (Using clinical trials)